Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity

被引：14

作者：

Harbaum, Lars ^{[1
]}

Marx, Andreas ^{[2
]}

Goekkurt, Eray

Schafhausen, Philippe ^{[1
]}

Atanackovic, Djordje ^{[1
]}

机构：

[1] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol Stem Cell Transplantat, D-20246 Hamburg, Germany

[2] Univ Med Ctr Hamburg Eppendorf, Inst Pathol, D-20246 Hamburg, Germany

来源：

INTERNATIONAL JOURNAL OF HEMATOLOGY | 2014年 / 99卷 / 01期

关键词：

Tyrosine kinase inhibitor; Chronic myeloid leukemia; Imatinib; Hepatotoxicity; Dasatinib; CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC-PHASE; CYTOGENETIC RESPONSES; MOLECULAR RESPONSE; DOSE IMATINIB; MESYLATE; MANAGEMENT; NILOTINIB; THERAPY; FAILURE;

D O I：

10.1007/s12185-013-1474-x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Treatment with the tyrosine kinase inhibitor (TKI) imatinib for chronic myeloid leukemia in chronic phase (CML-CP) of disease may cause severe hepatotoxicity in rare cases. However, it remains unclear (1) how imatinib-induced hepatotoxicity should be treated; and (2) if and how TKI treatment can be resumed after recovery. We report a 32-year-old woman with CML-CP and histology confirmed imatinib-induced liver toxicity after 6 months of treatment. In this case, the early administration of corticosteroid therapy resulted in rapid and complete hepatic recovery, and treatment for CML-CP with the second generation TKI dasatinib was continued safely after recovery. Thus, dasatinib represents an option for maintaining therapeutic response in patients in whom continuation of imatinib is not possible due to its hepatic toxicity.

引用

页码：91 / 94

页数：4

共 23 条

[1] European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 [J].

Baccarani, Michele ;

Deininger, Michael W. ;

Rosti, Gianantonio ;

Hochhaus, Andreas ;

Soverini, Simona ;

Apperley, Jane F. ;

Cervantes, Francisco ;

Clark, Richard E. ;

Cortes, Jorge E. ;

Guilhot, Francois ;

Hjorth-Hansen, Henrik ;

Hughes, Timothy P. ;

Kantarjian, Hagop M. ;

Kim, Dong-Wook ;

Larson, Richard A. ;

Lipton, Jeffrey H. ;

Mahon, Francois-Xavier ;

Martinelli, Giovanni ;

Mayer, Jiri ;

Mueller, Martin C. ;

Niederwieser, Dietger ;

Pane, Fabrizio ;

Radich, Jerald P. ;

Rousselot, Philippe ;

Saglio, Giuseppe ;

Saussele, Susanne ;

Schiffer, Charles ;

Silver, Richard ;

Simonsson, Bengt ;

Steegmann, Juan-Luis ;

Goldman, John M. ;

Hehlmann, Ruediger .

BLOOD, 2013, 122 (06) :872-884

[2] Imatinib mesylate as a cause of acute liver failure [J].

Cross, TJS ;

Bagot, C ;

Portmann, B ;

Wendon, J ;

Gillett, D .

AMERICAN JOURNAL OF HEMATOLOGY, 2006, 81 (03) :189-192

[3]

Ferrero Dario, 2006, Haematologica, V91, pECR27

[4] Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib [J].

Hochhaus, A. ;

Baccarani, M. ;

Deininger, M. ;

Apperley, J. F. ;

Lipton, J. H. ;

Goldberg, S. L. ;

Corm, S. ;

Shah, N. P. ;

Cervantes, F. ;

Silver, R. T. ;

Niederwieser, D. ;

Stone, R. M. ;

Dombret, H. ;

Larson, R. A. ;

Roy, L. ;

Hughes, T. ;

Mueller, M. C. ;

Ezzeddine, R. ;

Countouriotis, A. M. ;

Kantarjian, H. M. .

LEUKEMIA, 2008, 22 (06) :1200-1206

[5] Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment [J].

Hochhaus, Andreas ;

Druker, Brian ;

Sawyers, Charles ;

Guilhot, Francois ;

Schiffer, Charles A. ;

Cortes, Jorge ;

Niederwieser, Dietger W. ;

Gambacorti, Carlo ;

Stone, Richard M. ;

Goldman, John ;

Fischer, Thomas ;

O'Brien, Stephen G. ;

Reiffers, Jose J. ;

Mone, Manisha ;

Krahnke, Tillmann ;

Talpaz, Moshe ;

Kantarjian, Hagop M. .

BLOOD, 2008, 111 (03) :1039-1043

[6] Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy [J].

Hochhaus, Andreas ;

Kantarjian, Hagop M. ;

Baccarani, Michele ;

Lipton, Jeffrey H. ;

Apperley, Jane F. ;

Druker, Brian J. ;

Facon, Thierry ;

Goldberg, Stuart L. ;

Cervantes, Francisco ;

Niederwieser, Dietger ;

Silver, Richard T. ;

Stone, Richard M. ;

Hughes, Timothy P. ;

Muller, Martin C. ;

Ezzeddine, Rana ;

Countouriotis, Athena M. ;

Shah, Neil P. .

BLOOD, 2007, 109 (06) :2303-2309

[7] Educational Session: Managing Chronic Myeloid Leukemia as a Chronic Disease [J].

Hochhaus, Andreas .

HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM, 2011, :128-135

[8] Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management [J].

Ikuta, K ;

Torimoto, Y ;

Jimbo, J ;

Inamura, J ;

Shindo, M ;

Sato, K ;

Tokusashi, Y ;

Miyokawa, N ;

Kohgo, Y .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2005, 82 (04) :343-346

[9] Chronic myeloid leukemia: 2012 Update on diagnosis, monitoring, and management [J].

Jabbour, Elias ;

Kantarjian, Hagop .

AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (11) :1038-1045

[10] Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia [J].

Kantarjian, Hagop ;

Shah, Neil P. ;

Hochhaus, Andreas ;

Cortes, Jorge ;

Shah, Sandip ;

Ayala, Manuel ;

Moiraghi, Beatriz ;

Shen, Zhixiang ;

Mayer, Jiri ;

Pasquini, Ricardo ;

Nakamae, Hirohisa ;

Huguet, Francoise ;

Boque, Concepcion ;

Chuah, Charles ;

Bleickardt, Eric ;

Bradley-Garelik, M. Brigid ;

Zhu, Chao ;

Szatrowski, Ted ;

Shapiro, David ;

Baccarani, Michele .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (24) :2260-2270

← 1 2 3 →